| L01EX52 |
L01EX52 Quizartinib |
| L01EX53 |
L01EX53 Larotrectinib |
| L01EX54 |
L01EX54 Gilteritinib |
| L01EX56 |
L01EX56 Entrectinib |
| L01EX57 |
L01EX57 Fedratinib |
| L01F |
L01F Monoclonal antibodies and antibody drug conjugates |
| L01FA |
L01FA CD20 (Clusters of Differentiation 20) inhibitors |
| L01FA01 |
L01FA01 Rituximab |
| L01FA02 |
L01FA02 Ofatumumab |
| L01FA03 |
L01FA03 Obinutuzumab |
| L01FB |
L01FB CD22 (Clusters of Differentiation 22) inhibitors |
| L01FB01 |
L01FB01 Inotuzumab ozogamicin |
| L01FB02 |
L01FB02 Moxetumomab pasudotox |
| L01FC |
L01FC CD38 (Clusters of Differentiation 38) inhibitors |
| L01FC01 |
L01FC01 Daratumumab |
| L01FC02 |
L01FC02 Isatuximab |
| L01FD |
L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors |
| L01FD01 |
L01FD01 Trastuzumab |
| L01FD02 |
L01FD02 Pertuzumab |
| L01FD03 |
L01FD03 Trastuzumab emtansine |
| L01FD04 |
L01FD04 Trastuzumab deruxtecan |
| L01FD05 |
L01FD05 Trastuzumab duocarmazine |
| L01FD06 |
L01FD06 Margetuximab |
| L01FD07 |
L01FD07 Zanidatamab |
| L01FE |
L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors |
| L01FE01 |
L01FE01 Cetuximab |
| L01FE02 |
L01FE02 Panitumumab |
| L01FE03 |
L01FE03 Necitumumab |
| L01FF |
L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| L01FF01 |
L01FF01 Nivolumab |